Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • FDA Raises Fresh Safety Concerns Over Unapproved GLP-1 Weight-Loss Drugs
    3 September 2026

    FDA Raises Fresh Safety Concerns Over Unapproved GLP-1 Weight-Loss Drugs

    The U.S. Food and Drug Administration (FDA) has issued a detailed warning about the risks associated with unapproved and compounded GLP-1 drugs being used for weight loss, highlighting concerns related to product quality, dosing errors, counterfeit medicines and improper storage.

  • Gland Pharma’s Visakhapatnam Facilities Clear USFDA Inspection With Zero Observations
    3 September 2026
    Gland Pharma’s Visakhapatnam Facilities Clear USFDA Inspection With Zero Observations

    Gland Pharma Limited has announced the successful conclusion of a routine Good Manufacturing Practice (GMP) inspection conducted by the United States Food and Drug Administration (USFDA) at its facilities in Visakhapatnam.

    The inspection was carried out at the company’s VSEZ Sterile Oncology Formulations Facility and API Facility in Visakhapatnam. The regulatory inspection commenced on August 24, 2026, and concluded on September 1, 2026.

  • VEGFR Inhibitors Show Strong Pancreatic Tumor Control in Metastatic Kidney Cancer Study
    3 September 2026
    VEGFR Inhibitors Show Strong Pancreatic Tumor Control in Metastatic Kidney Cancer Study

    A new study published in Acta Clinica Belgica has found that vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) can produce substantial tumor shrinkage in patients with metastatic clear-cell renal cell carcinoma (ccRCC) involving the pancreas.

  • Adalimumab Emerges as Most Cost-Efficient Biologic for Hidradenitis Suppurativa, Study Finds
    3 September 2026
    Adalimumab Emerges as Most Cost-Efficient Biologic for Hidradenitis Suppurativa, Study Finds
    A new economic evaluation published in JAMA Dermatology has found that adalimumab 40 mg administered weekly offers the most consistent balance between treatment effectiveness and cost among currently approved monoclonal antibody therapies for hidradenitis suppurativa (HS).
  • ARPA-H Backs 125 Million USD Drive to Enable On-Demand Manufacturing of Personalized RNA Medicines
    3 September 2026
    ARPA-H Backs 125 Million USD Drive to Enable On-Demand Manufacturing of Personalized RNA Medicines

    The Advanced Research Projects Agency for Health (ARPA-H) has selected five research teams to develop new technologies aimed at making individualized, RNA-based genetic medicines faster and more accessible.

    The initiative is part of ARPA-H’s Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program, which could receive up to 125 million USD in research and development funding. The program seeks to establish an automated, distributed manufacturing network capable of producing genetic medicines on demand and closer to the point of care.

  • Dry Eye Remains an Overlooked Menopause Symptom, Bausch and Lomb Survey Reveals
    2 September 2026
    Dry Eye Remains an Overlooked Menopause Symptom, Bausch and Lomb Survey Reveals
    Dry eye is significantly underrecognized as a symptom associated with perimenopause and menopause, according to findings from a new survey conducted by Bausch + Lomb. The survey highlights a substantial awareness gap among women and points to the need for greater attention to eye health during this stage of life.
  • Novartis’ Remibrutinib Delivers Positive Phase III Results in Relapsing Multiple Sclerosis
    2 September 2026
    Novartis’ Remibrutinib Delivers Positive Phase III Results in Relapsing Multiple Sclerosis

    Novartis has announced positive topline results from the Phase III REMODEL-1 and REMODEL-2 trials evaluating remibrutinib, an oral Bruton’s tyrosine kinase (BTK) inhibitor, in adults with relapsing multiple sclerosis (RMS).

    The investigational therapy met the primary endpoint in both trials, demonstrating a statistically significant reduction in annualized relapse rate (ARR) compared with teriflunomide. The studies also reported favorable results across key secondary endpoints, including measures of inflammatory brain lesions seen on MRI.

  • Zydus Reports Positive Phase II(b) Results for Saroglitazar Mg in MASH
    1 September 2026
    Zydus Reports Positive Phase II(b) Results for Saroglitazar Mg in MASH

    Zydus Lifesciences has announced positive topline results from its global EVIDENCES-X™ Phase II(b) clinical trial evaluating Saroglitazar Magnesium in patients with Metabolic dysfunction-Associated Steatohepatitis (MASH) and fibrosis. The company said the study successfully achieved its primary endpoint, marking an important milestone in its ongoing MASH development programme.

  • ₹5,000 Crore PRIP Scheme Opens Second Funding Round for Pharma and MedTech Innovation
    1 September 2026
    ₹5,000 Crore PRIP Scheme Opens Second Funding Round for Pharma and MedTech Innovation
    Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has announced the second call for applications under the Promotion of Research and Innovation in Pharma & MedTech (PRIP) Scheme, creating fresh funding opportunities for startups, MSMEs and pharmaceutical and MedTech companies working on high-impact innovations.
  • Trump Administration Adds Nine Pharma Companies to U.S. Drug Price-Cut Deal; Sun Pharma, Teva Among Signatories
    1 September 2026
    Trump Administration Adds Nine Pharma Companies to U.S. Drug Price-Cut Deal; Sun Pharma, Teva Among Signatories

    The Trump administration has announced agreements with nine additional pharmaceutical manufacturers aimed at reducing prescription drug prices in the United States under its Most-Favored-Nation (MFN) pricing initiative.

    The latest agreements bring the total number of pharmaceutical manufacturers participating in the administration's MFN arrangements to 26 companies, covering approximately 89% of the branded drug market, according to a White House fact sheet released on August 31.

Subscribe to Pharma News